3 unknown, 1 not yet recruiting, 1 terminated. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Unknown 3, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 3 | Unknown 2, Not yet recruiting 1 |
Follow PD-1: new trials by email Literature Review of PD-1 trials Research Report on PD-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma PD-1+JAK1i, PD-1 - Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 112 | 2026-06-30 | 2026-06-11 |
| Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer GLS-012+GLS-010, GLS-012+GLS-010+pemetrexed+carboplatin, GLS-012+GLS-010+paclitaxel+carboplatin - Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Guangzhou Gloria Biosciences Co., Ltd. | 152 | 2023-08-10 | 2023-08-07 |
| Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors iNeo-Vac-P01, GM-CSF, PD-1 - Advanced Malignant Solid Tumor | Phase 1 | Unknown | Sir Run Run Shaw Hospital | 30 | 2020-09-03 | 2021-04-28 |
| Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ PD-1 - PD-1, Chemoradiotherapy | Phase 1 / Phase 2 | Unknown | Peking University | 45 | 2019-08-26 | 2019-08-20 |
| The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors SHR7390, SHR-1210, SHR3162 - Solid Tumor | Phase 1 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 31 | 2017-07-24 | 2022-09-01 |
Hodgkin Disease (1)
Guangzhou Gloria Biosciences Co., Ltd. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Peking University (1) · Shanghai Jiao Tong University School of Medicine (1) · Sir Run Run Shaw Hospital (1)
China (4)
RuiHua Xu, MD, PhD (1) · Yongheng Li, MD (1) · Ziyu Li, MD (1)